NBIX - NEUROCRINE BIOSCIENCES INC

QQQ $ 473.83 $ 0.25 (0.05 %)

DIA $ 417.12 $ -0.12 (-0.03 %)

SPY $ 563.14 $ 0.23 (0.04 %)

TLT $ 100.82 $ -0.49 (-0.48 %)

GLD $ 237.35 $ -1.32 (-0.55 %)

Previous Close

$ 122.31

Open

$ 122.99

Bid

$ 122.31 x 100

Ask

$ 122.40 x 100

Day's Range

$ 121.00 - $ 123.13

52 Week Range

$ 103.63 - $ 157.98

Volume

757,338

Average Volume

Market Cap

12.35B

Beta (5Y Monthly)

$ 0.57

PE Ratio (TTM)

$ 36.41

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-01-2024	03-31-2024	10-Q
3	02-09-2024	12-31-2023	10-K
4	10-31-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-03-2023	03-31-2023	10-Q
7	02-09-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	02-11-2022	12-31-2021	10-K
12	11-01-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	02-05-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-03-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	02-07-2020	12-31-2019	10-K
20	11-04-2019	09-30-2019	10-Q
21	07-29-2019	06-30-2019	10-Q
22	04-29-2019	03-31-2019	10-Q
23	02-08-2019	12-31-2018	10-K
24	11-05-2018	09-30-2018	10-Q
25	07-31-2018	06-30-2018	10-Q
26	04-30-2018	03-31-2018	10-Q
27	02-13-2018	12-31-2017	10-K
28	11-01-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	02-14-2017	12-31-2016	10-K
32	11-02-2016	09-30-2016	10-Q
33	08-03-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q
35	02-11-2016	12-31-2015	10-K
36	10-29-2015	09-30-2015	10-Q
37	07-29-2015	06-30-2015	10-Q
38	04-30-2015	03-31-2015	10-Q
39	02-09-2015	12-31-2014	10-K
40	11-04-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 16:21:25

Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $15...

neurocrine-shifts-focus-to-new-schizophrenia-treatment-after-luvadaxistat-trial-misses-endpoint

Neurocrine Shifts Focus To New Schizophren...
09/13/2024 16:00:31

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treatin...

Neurocrine Biosciences Provides Update on ...
09/12/2024 20:11:13

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated...

Decoding 19 Analyst Evaluations For Neuroc...
09/09/2024 15:01:08

Barclays Maintains Overweight on Neurocrin...
09/09/2024 13:41:36

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target f...

intel-moderna-and-dollar-general-were-among-top-10-large-cap-losers-in-august-are-the-others-in-your-portfolio

Intel, Moderna And Dollar General Were Amo...
09/08/2024 17:05:02

10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fie...

dollar-general-temu-parent-pdd-and-super-micro-computer-are-among-top-10-large-cap-losers-last-week-aug-25-aug-31-are-the-others-in-your-portfolio

Dollar General, Temu Parent PDD And Super ...
09/02/2024 13:55:17

10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Bio...

neurocrine-biosciences-lower-dose-data-puts-its-schizophrenia-candidate-in-the-game-analyst-upgrades-stock

Neurocrine Biosciences' Lower Dose Data Pu...
08/29/2024 17:22:04

Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant...

Cantor Fitzgerald Maintains Overweight on ...
08/29/2024 15:37:27

Cantor Fitzgerald analyst Charles Duncan maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the pri...

RBC Capital Maintains Sector Perform on Ne...
08/29/2024 13:39:19

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Sector Perform and lowers the price...

nvidia-to-rally-over-31-here-are-10-top-analyst-forecasts-for-thursday

NVIDIA To Rally Over 31%? Here Are 10 Top ...
08/29/2024 12:45:22

HC Wainwright & Co. Reiterates Buy on Neur...
08/29/2024 11:37:49

HC Wainwright & Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $190 pr...

Needham Reiterates Hold on Neurocrine Bios...
08/29/2024 09:40:14

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.

Piper Sandler Upgrades Neurocrine Bioscien...
08/29/2024 09:33:49

Piper Sandler analyst David Amsellem upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Neutral to Overweight and raises the...

BMO Capital Maintains Market Perform on Ne...
08/29/2024 09:12:43

BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price...

nasdaq-down-over-1-foot-locker-shares-tumble-after-q2-results

Nasdaq Down Over 1%; Foot Locker Shares Tu...
08/28/2024 16:56:36

as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-data-disappoints-investors

As Regulators Gear Up To Decide On Bristol...
08/28/2024 15:16:26

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...

us-stocks-mixed-jm-smucker-slashes-annual-guidance

US Stocks Mixed; JM Smucker Slashes Annual...
08/28/2024 13:59:55

Neurocrine Biosciences Announced Positive ...
08/28/2024 11:09:09

regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna

Regulators Expected To Approve Innovative ...
08/27/2024 19:22:11

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...